A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 3, 2009, Pages 469-476

  Kathman, Steven J ^a   Williams, Daphne H ^a   Hodge, Jeffrey P ^a   Dar, Mohammed ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Absolute neutrophil count; Bayesian methods; Myelosuppression; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DOCETAXEL; ISPINESIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; QUINAZOLINE DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD CELL; BONE MARROW SUPPRESSION; CELL COMPARTMENTALIZATION; CELL MATURATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCESS MODEL; BONE MARROW; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BENZAMIDES; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIDDLE AGED; QUINAZOLINES; TAXOIDS;

EID: 58249141626     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0760-4     Document Type: Article

References (16)

1. P Baille R Bruno J Schellens L Webster M Millward J Verweij G Montay 1997 Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance Clin Cancer Res 3 1535 1538 (Pubitemid 27431560)
2. Blagden S, Molife L, Seebaran A, Payne M, Reid A, Protheroe A, Vasist L, Williams D, Bowen C, Kathman S, Hodge J, Dar M, de Bono J, Middleton M (2008) A phase I trial of ispinesib, a kinesin spindle protein inhibitor, in combination with docetaxel in patients with advanced solid tumors. Br J Cancer (to appear)
3. R Bruno N Vivier J Vergniol S De Phillips G Montay L Sheiner 1996 A population pharmacokinetic model for docetaxel: model building and validation J Pharmacokinet Biopharm 24 2 153 172 (Pubitemid 26300483)
4. S Duffull C Kirkpatrick B Green N Holford 2005 Analysis of populations pharmacokinetic data using NONMEM and WinBugs J Biopharm Stat 15 53 73 (Pubitemid 40130000)
5. L Friberg A Henningsson H Maas L Nguyen M Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 4713 4721 (Pubitemid 36025290)
6. L Friberg M Karlsson 2003 Mechanistic models for myelosuppression Invest New Drugs 21 183 194 (Pubitemid 36859318)
7. Gelman A, Carlin JB, Stern HS, Rubin DB (2003) Bayesian data analysis. Chapman & Hall, London
8. S Kathman D Williams J Hodge M Dar 2007 A Bayesian population PK-PD model of ispinesib induced myelosuppression Clin Pharmacol Ther 81 1 88 94 (Pubitemid 46050871)
9. J Latz M Karlsson J Rusthoven A Ghosh R Johnson 2006 A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy Cancer Chemother Pharmacol 57 412 426 (Pubitemid 43087584)
10. M Launay-Iliadis R Bruno V Cosson J Vergniol D Oulid-Aissa M Marty M Clavel M Aapro N LeBail A Iliadis 1995 Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modelling and nonparametric maximum-likelihood estimation Cancer Chemother Pharmacol 37 47 54
11. D Lunn N Best A Thomas J Wakefield D Spiegelhalter 2002 Bayesian analysis of population PK/PD models: general concepts and software J Pharmacokinet Pharmacodyn 29 271 307 (Pubitemid 35333143)
12. DJ Lunn A Thomas N Best D Spiegelhalter 2000 WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility Stat Comput 10 325 337
13. Robert C, Casella G (2004) Monte Carlo statistical methods. Springer, New York
14. M Sandstrom H Lindman P Nygren E Lidbrink J Bergh MO Karlsson 2005 Model describing the relationship between pharmacokinetics and hematologic toxicity of the Epirubicin-Docetaxel regimen in breast cancer patients J Clin Oncol 23 3 413 421 (Pubitemid 46224216)
15. M Sandstrom H Lindman P Nygren M Johansson J Bergh MO Karlsson 2006 Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients Cancer Chemother Pharmacol 58 143 156
16. I Troconiz M Garrido C Segura J Cendros P Principe C Peraire R Obach 2006 Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours Cancer Chemother Pharmacol 57 727 735